Drugs in R & D

, Volume 8, Issue 6, pp 383–391 | Cite as

Influence of Piperine on the Pharmacokinetics of Nevirapine under Fasting Conditions

A Randomised, Crossover, Placebo-Controlled Study
  • Ravisekhar Kasibhatta
  • M. U. R. Naidu
Original Research Article


Background: Nevirapine is a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase and is indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. Piperine (1-piperoylpiperidine) is an alkaloid and the main pungency principle in both black and long pepper. There are indications that piperine inhibits, rather than stimulates, drug metabolism in most cases, thus increasing the bioavailability and effect of some drugs.

Methods: This was a crossover, placebo-controlled pilot study conducted in a total of eight healthy adult males aged 20–40 years. Subjects were randomly assigned to receive piperine 20mg or placebo each morning for 6 days, and on day 7, nevirapine 200mg plus piperine 20mg or nevirapine plus placebo in a crossover fashion. Blood samples were collected from 1 to 144 hours post-dose for pharmacokinetic analysis.

Results: Mean maximum plasma concentration (Cmax), area under the plasma concentration-time curve from 0 hours to the last measurable concentration (Clast) [AUCt], AUC extrapolated to infinity (AUC∞) and Clast values of nevirapine were increased by approximately 120%, 167%, 170% and 146%, respectively, when co-administered with piperine. The treatments were well tolerated, indicating few or no clinical adverse effects.

Conclusion: This pilot study provided evidence for enhanced bioavailability of nevirapine when administered with piperine. Further in-depth studies in a large number of patients receiving different dosage regimens are required to confirm these results and further our understanding of a possible clinical advantage arising from the bioenhancement capabilities of piperine in the treatment of HIV infection.


Felodipine Nevirapine Piperine Complementary Alternative Medicine Nevirapine Absorption 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to assist with this study. The authors are grateful to the staff of Bioserve Clinical Research Pvt Ltd, Hyderabad, India for conducting the clinical phase of the study, and to the bioanalytical staff of the Department of Clinical Pharmacology and Pharmacokinetics of Dr Reddy’s Laboratories, Generics Division, Hyderabad, India for analysis of the clinical samples. The authors have no potential conflicts of interest that are directly relevant to the content of this study, which was conducted as part of a PhD programme of one of the authors.


  1. 1.
    UNAIDS: the Joint United Nations Programme on HIV/AIDS Web site [online]. Available at URL: Unaids/EN/Resources/Epidemiology/epidemicupdateslides.asp / Unaids/EN/Resources/Epidemiology/epidemicupdateslides.asp [Accessed 2004 Aug 17]
  2. 2.
    US Department of Health and Human Services (DHHS). HIV/AIDS medical practice guidelines [online]. Available at URL: [Accessed 2004 Aug
  3. 3.
    Nolan D. Metabolic complications associated with HIV protease inhibitor therapy. Drugs 2003; 63: 2555–74PubMedCrossRefGoogle Scholar
  4. 4.
    Van Leeuwen R, Katlama C, Murphy RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 2003; 17: 987–99PubMedCrossRefGoogle Scholar
  5. 5.
    Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341: 1865–73PubMedCrossRefGoogle Scholar
  6. 6.
    Yozviak JL, Doerfler RE, Woodward WC. Effectiveness and tolerability of nevirapine, stavudine, and lamivudine in clinical practice. HIV Clin Trials 2001; 2: 474–6PubMedCrossRefGoogle Scholar
  7. 7.
    Laurent C, Kouanfack C, Koulla-Shiro S, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004; 364: 29–34PubMedCrossRefGoogle Scholar
  8. 8.
    van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial. The 2NN Study. Lancet 2004; 363: 1253–63PubMedCrossRefGoogle Scholar
  9. 9.
    Floridia M, Bucciardini R, Ricciardulli D, et al. A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 11–9PubMedCrossRefGoogle Scholar
  10. 10.
    Lamson MJ, Cort S, Sabo JP, et al. Assessment of nevirapine oral bioavailability in healthy volunteers following oral and intravenous administration. Pharm Res 1995; 12: S–415Google Scholar
  11. 11.
    Lamson MJ, Sabo JP, MacGregor TR, et al. Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. Biopharm Drug Dispos 1999 Sep; 20 (6): 285–91PubMedCrossRefGoogle Scholar
  12. 12.
    Viramune (nevirapine) [online]. Available from URL: [Accessed 2007 Oct 19]
  13. 13.
    Riska P, Lamson M, MacGregor T, et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 1999 Aug; 27 (8): 895–901PubMedGoogle Scholar
  14. 14.
    Hu Z, Yang X, Ho PC, et al. Herb-drug interactions: a literature review. Drugs 2005; 65 (9): 1239–82PubMedCrossRefGoogle Scholar
  15. 15.
    Baily DG, Malcolm J, Arnold O, et al. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998; 46: 101–10CrossRefGoogle Scholar
  16. 16.
    Kane GC, Lipsky JJ. Drug-grapefruit juice interactions. Mayo Clin Proc 2000; 75: 933–42PubMedCrossRefGoogle Scholar
  17. 17.
    Atal CK, Zutshi U, Rao PG Scientific evidence on the role of Ayurvedic herbals on bioavailability of drugs. J Ethnopharmacol 1981; 4: 229–32PubMedCrossRefGoogle Scholar
  18. 18.
    Zutshi RK, Singh R, Zutshi U, et al. Influence of piperine on rifampicin blood levels in patients of pulmonary tuberculosis. J Assoc Physicians India 1985; 33: 223–4PubMedGoogle Scholar
  19. 19.
    Bano G, Raina RK, Zutshi U, et al. Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers. Eur J Clin Pharmacol 1991; 41 (6): 615–7PubMedCrossRefGoogle Scholar
  20. 20.
    Velpandian T, Jasuja R, Bhardwaj RK, et al. Piperine in food: interference in the pharmacokinetics of phenytoin. Eur J Drug Metab Pharmacokinet 2001 Oct–Dec; 26 (4): 241–7PubMedCrossRefGoogle Scholar
  21. 21.
    Koul IB, Kapil A. Evaluation of the liver protective potential of piperine, an active principle of black and long peppers. Planta Med 1993 Oct; 59 (5): 413–7PubMedCrossRefGoogle Scholar
  22. 22.
    Singh J, Dubey RK, Atal CK. Piperine-mediated inhibition of glucuronidation activity in isolated epithelial cells of the guinea-pig small intestine: evidence that piperine lowers the endogenous UDP-glucuronic acid content. J Pharmacol Exp Ther 1986; 236: 488–93PubMedGoogle Scholar
  23. 23.
    Narang VS, Lulla A, Malhotra G, et al. A combined-formulation tablet of lamivudine/nevirapine/stavudine: bioequivalence compared with concurrent administration of lamivudine, nevirapine, and stavudine in healthy Indian subjects. J Clin Pharmacol 2005; 45: 265–74PubMedCrossRefGoogle Scholar
  24. 24.
    Viramune (nevirapine) [product information]. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals, 1999Google Scholar
  25. 25.
    Pattanaik S, Hota D, Prabhakar S, et al. Effect of piperine on the steady-state pharmacokinetics of phenytoin in patients with epilepsy. Phytother Res 2006 Aug; 20 (8): 683–6PubMedCrossRefGoogle Scholar
  26. 26.
    King JR, Yogev R, Aldrovandi G, et al. Pharmacokinetics of antiretrovirals administered to HIV-infected children via gastrostomy tube. HIV Clin Trials 2004 Sep–Oct; 5 (5): 288–93PubMedCrossRefGoogle Scholar
  27. 27.
    Bhardwaj RK, Glaeser H, Becquemont L, et al. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Experiment Therapeut 2002; 302: 645–50CrossRefGoogle Scholar
  28. 28.
    Stern JO, Robinson PA, Love J, et al. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003; 34 Suppl. 1: S21–33PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Department of Clinical Pharmacology and TherapeuticsNizam’s Institute of Medical SciencesHyderabadIndia

Personalised recommendations